Studies how often inhibitors develop in hemophilia A patients using Coageight
Looks at how often inhibitors develop in people with hemophilia A treated with Coageight.
Plain-language title generated from the registry record
Registry title: Prevalence of Inhibitor Development in Hemophilia A Patients Receiving Coageight: A Multicenter Cross-sectional Observational Study
Key facts
- Where
- Ahvāz, Isfahan, Mashhad, Shiraz, and Tehran, IranSee the 6 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for boys and men with hemophilia A who have used Coageight for some time. It checks how many have developed inhibitors.
- Age
- 2 years or older
- Sex
- Male only
- Disease stage
- Hemophilia A
- Earlier treatment
- At least 50 exposure days to any FVIII product. At least 10 exposure days with Coageight in the past 12 months.
Main reasons for not taking part
- Any other bleeding (coagulation) disorder besides hemophilia A
- Immune system deficiency disorders, unless they had Immune Tolerance Induction (ITI) for inhibitors
- Hepatitis B or C
- Taking part, or planning to take part, in another research study during this study
- Cannot or will not follow the study requirements
Read by machine on 13 November 2026.
Where in Iran
- Shahid Baqaei 2 HospitalAhvāz, IranContact: Bijan KeykhaiNo longer taking part
- Seyyed al-Shohada HospitalIsfahan, IranContact: Majid QanavatNo longer taking part
- Soroor ClinicMashhad, IranContact: Zahra BadieiNo longer taking part
- Shahid Ayatollah Dastgheib HospitalShiraz, IranContact: Mohammadreza BordbarNo longer taking part
- Imam Khomeini HospitalTehran, IranContact: Mohammadreza ShaverdiNo longer taking part
- Mofid Children's HospitalTehran, IranContact: Samin Alavi BojestaniNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AryoGen Pharmed Co.
- Trial code
- NCT07791836
- Record updated
- 28 August 2026
- Original description
This is a cross-sectional, observational, multi-center study to assess the prevalence of inhibitor development in hemophilia A patients receiving Coageight (rFVIII-Fc, AryoGen Pharmed Co.).Read full original descriptionShow less
A Cross-sectional, Observational, Multi-center Study to Assess the Prevalence of Inhibitor Development in Hemophilia A Patients Receiving Coageight (rFVIII-Fc, Manufactured by AryoGen Pharmed Co.)
This is a cross-sectional, observational, multi-center study to assess the prevalence of inhibitor development in hemophilia A patients receiving Coageight (rFVIII-Fc, AryoGen Pharmed Co.).
Inclusion: Male patients aged 2 years or older with a signed informed consent by them or their legal guardian; Hemophilia A patients with ≥ 50 exposure days to any FVIII product, based on the patient's medical record and the physician's opinion; History of receiving at least 10 exposure days with Coageight during the past 12 months, based on the patient's medical records and the physician's opinion.
Exclusion: History of any other coagulation disorders except hemophilia A and disorders related to immune system deficiencies (except for the patients who have undergone Immune Tolerance Induction (ITI) treatment due to inhibitor formation); Patients with hepatitis B or C (based on the patient's medical records), due to potential interference with the inhibitor assessments; Participation or intent to participate in another research study during this study period; Inability or unwillingness of the patient to meet the protocol requirements, as determined by the physician (e.g., physical or psychological issues).